JPWO2020057511A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020057511A5 JPWO2020057511A5 JP2021514381A JP2021514381A JPWO2020057511A5 JP WO2020057511 A5 JPWO2020057511 A5 JP WO2020057511A5 JP 2021514381 A JP2021514381 A JP 2021514381A JP 2021514381 A JP2021514381 A JP 2021514381A JP WO2020057511 A5 JPWO2020057511 A5 JP WO2020057511A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- yloxy
- pyrimidin
- methylphenyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920006395 saturated elastomer Polymers 0.000 claims description 89
- 125000000623 heterocyclic group Chemical group 0.000 claims description 83
- 125000000217 alkyl group Chemical group 0.000 claims description 78
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 47
- 229910052736 halogen Inorganic materials 0.000 claims description 44
- 150000002367 halogens Chemical class 0.000 claims description 44
- 125000003342 alkenyl group Chemical group 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 30
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- 125000002252 acyl group Chemical group 0.000 claims description 26
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 26
- 125000001188 haloalkyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 20
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 20
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 20
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- -1 nitro, hydroxyl Chemical group 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 230000008499 blood brain barrier function Effects 0.000 claims description 12
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 206010027476 Metastases Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- ZKRGDRIWZDUEPQ-MDNUFGMLSA-N 5-[(1R,5R)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@@H]2CCN([C@@H]2C1)C)O[C@@H]1COCC1)C ZKRGDRIWZDUEPQ-MDNUFGMLSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000005945 translocation Effects 0.000 claims description 3
- XZWQXDUAEYDLMF-SRDVKXRDSA-N (5S)-6-(difluoromethoxy)-5-(3,3-difluoro-1-methylpiperidin-4-yl)oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6H-quinazolin-5-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)N[C@@]1(C=2C=NC=NC=2C=CC1OC(F)F)OC1C(CN(CC1)C)(F)F)C XZWQXDUAEYDLMF-SRDVKXRDSA-N 0.000 claims description 2
- XVWWYSCPCWFSKB-VOTSOKGWSA-N (E)-4-(dimethylamino)-N-[5-[3-(dimethylamino)azetidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]but-2-enamide Chemical compound CC1=C(C=CC(=C1)NC2=NC=NC3=C2C(=C(C=C3)NC(=O)/C=C/CN(C)C)N4CC(C4)N(C)C)OC5=CC6=NC=NN6C=N5 XVWWYSCPCWFSKB-VOTSOKGWSA-N 0.000 claims description 2
- XDEPOFKWJQCAOD-LZPATWBJSA-N (E)-N-[3-cyano-5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound CC1=C(C=CC(=C1)NC2=C3C(=NC=C2C#N)C=CC(=C3O[C@@H]4CCN(CC4(F)F)C)NC(=O)/C=C/[C@H]5CCCN5C)OC6=CC7=NC=NN7C=N6 XDEPOFKWJQCAOD-LZPATWBJSA-N 0.000 claims description 2
- KXZRACJXPFTXCJ-IQKOXAACSA-N (E)-N-[3-cyano-5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound CC1=C(C=CC(=C1)NC2=C3C(=NC=C2C#N)C=CC(=C3O[C@@H]4CCN(CC4(F)F)C)NC(=O)/C=C/CN(C)C)OC5=CC6=NC=NN6C=N5 KXZRACJXPFTXCJ-IQKOXAACSA-N 0.000 claims description 2
- YRHMDFJNKYQMLD-UWSNOUECSA-N (E)-N-[3-cyano-5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound CCOC1=C(C(=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OC4=CC5=NC=NN5C=N4)C)C#N)O[C@@H]6CCN(CC6(F)F)C)NC(=O)/C=C/CN(C)C YRHMDFJNKYQMLD-UWSNOUECSA-N 0.000 claims description 2
- LVUHOOHMDJWZHA-NQOLIALDSA-N (E)-N-[5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound CC1=C(C=CC(=C1)NC2=NC=NC3=C2C(=C(C=C3)NC(=O)/C=C/[C@H]4CCCN4C)O[C@@H]5CCN(CC5(F)F)C)OC6=CC7=NC=NN7C=N6 LVUHOOHMDJWZHA-NQOLIALDSA-N 0.000 claims description 2
- XFSWJJJODOWIQL-GJCNFQEQSA-N (E)-N-[5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(=CC=C2C(=C1O[C@@H]1CCN(CC1(F)F)C)C(NC1=CC(=C(C=C1)OC=1N=CN3N=CN=C3C=1)C)=NC=N2)NC(=O)/C=C/CN(C)C XFSWJJJODOWIQL-GJCNFQEQSA-N 0.000 claims description 2
- ZNZLYQXLYDJAMP-XALOKNAFSA-N (E)-N-[5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound CCOC1=C(C(=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)OC4=CC5=NC=NN5C=N4)C)O[C@@H]6CCN(CC6(F)F)C)NC(=O)/C=C/[C@H]7CCCN7C ZNZLYQXLYDJAMP-XALOKNAFSA-N 0.000 claims description 2
- CHXBHABTRUNWBN-DIJOXEGBSA-N (E)-N-[5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound CCOC1=C(C(=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)OC4=CC5=NC=NN5C=N4)C)O[C@@H]6CCN(CC6(F)F)C)NC(=O)/C=C/CN(C)C CHXBHABTRUNWBN-DIJOXEGBSA-N 0.000 claims description 2
- AIWKOBLDEVRENR-ZRGXPQFDSA-N (E)-N-[5-[3-(dimethylamino)azetidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound CC1=C(C=CC(=C1)NC2=NC=NC3=C2C(=C(C=C3)NC(=O)/C=C/[C@H]4CCCN4C)N5CC(C5)N(C)C)OC6=CC7=NC=NN7C=N6 AIWKOBLDEVRENR-ZRGXPQFDSA-N 0.000 claims description 2
- GXNCGXCLKIERMB-HHHXNRCGSA-N 1-[4-[5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one Chemical compound C1(=CCN(CC1)C(=O)C=C)C1=C(O[C@@H]2CCN(CC2(F)F)C)C2=C(NC3=CC=C(OC=4N=CN5N=CN=C5C=4)C(C)=C3)N=CN=C2C=C1 GXNCGXCLKIERMB-HHHXNRCGSA-N 0.000 claims description 2
- OOFIFMBWTZZRRM-UHFFFAOYSA-N 1-[4-[5-[3-(dimethylamino)azetidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(C1)N(C)C)C=1CCN(CC=1)C(C=C)=O)C OOFIFMBWTZZRRM-UHFFFAOYSA-N 0.000 claims description 2
- SCSVJBGTAYSBRS-UHFFFAOYSA-N 1-[4-[5-[3-(dimethylamino)azetidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-7-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC(=CC(=C12)N1CC(C1)N(C)C)C=1CCN(CC=1)C(C=C)=O)C SCSVJBGTAYSBRS-UHFFFAOYSA-N 0.000 claims description 2
- RRRIANKHYKUUSN-UHFFFAOYSA-N 1-[4-[5-[3-(dimethylamino)pyrrolidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(CC1)N(C)C)OC1CCN(CC1)C(C=C)=O)C RRRIANKHYKUUSN-UHFFFAOYSA-N 0.000 claims description 2
- JOWVFZSEIHHQAE-UHFFFAOYSA-N 1-[5-[5-[3-(dimethylamino)azetidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(C1)N(C)C)C1=CCCN(C1)C(C=C)=O)C JOWVFZSEIHHQAE-UHFFFAOYSA-N 0.000 claims description 2
- CKOFGCXDBATTOY-UHFFFAOYSA-N 1-[5-[5-[3-(dimethylamino)azetidin-1-yl]-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-7-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC(=CC(=C12)N1CC(C1)N(C)C)C1=CCCN(C1)C(C=C)=O)C CKOFGCXDBATTOY-UHFFFAOYSA-N 0.000 claims description 2
- NSQIBSJKZMXNTE-UHFFFAOYSA-N 5-(2-cyclopropyl-2,6-diazabicyclo[3.2.0]heptan-6-yl)-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C2CCN(C2C1)C1CC1)OC)C NSQIBSJKZMXNTE-UHFFFAOYSA-N 0.000 claims description 2
- XBOGWTVNNYYDGG-UHFFFAOYSA-N 5-(7,7-difluoro-5-methyl-2,5-diazaspiro[3.4]octan-2-yl)-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CC(C2)(F)F)C)OC)C XBOGWTVNNYYDGG-UHFFFAOYSA-N 0.000 claims description 2
- XBOGWTVNNYYDGG-HPRDVNIFSA-N 5-(7,7-difluoro-5-methyl-2,5-diazaspiro[3.4]octan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trideuteriomethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CC(C2)(F)F)C)OC([2H])([2H])[2H])C XBOGWTVNNYYDGG-HPRDVNIFSA-N 0.000 claims description 2
- YRRGTHJHIGWEMW-NRFANRHFSA-N 5-(7,7-difluoro-5-methyl-2,5-diazaspiro[3.4]octan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CC(C2)(F)F)C)O[C@@H]1COCC1)C YRRGTHJHIGWEMW-NRFANRHFSA-N 0.000 claims description 2
- SMJRRAAHDXKYCQ-UHFFFAOYSA-N 5-(8-methyl-5-oxa-2,8-diazaspiro[3.5]nonan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=CC(=C12)N1CC2(C1)OCCN(C2)C)C SMJRRAAHDXKYCQ-UHFFFAOYSA-N 0.000 claims description 2
- JXQKQNNMNCWTIW-RSJQNUHWSA-N 5-[(1R,5R)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trideuteriomethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@@H]2CCN([C@@H]2C1)C)OC([2H])([2H])[2H])C JXQKQNNMNCWTIW-RSJQNUHWSA-N 0.000 claims description 2
- IAMGOGVQPSKQQH-FGZHOGPDSA-N 5-[(1R,5R)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-propan-2-yloxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@@H]2CCN([C@@H]2C1)C)OC(C)C)C IAMGOGVQPSKQQH-FGZHOGPDSA-N 0.000 claims description 2
- MQGBVXUNEXCWHU-SFTDATJTSA-N 5-[(1S,5S)-2-(2-fluoroethyl)-2,6-diazabicyclo[3.2.0]heptan-6-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)CCF)OC)C MQGBVXUNEXCWHU-SFTDATJTSA-N 0.000 claims description 2
- JXQKQNNMNCWTIW-JVBJWZIXSA-N 5-[(1S,5S)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trideuteriomethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C)OC([2H])([2H])[2H])C JXQKQNNMNCWTIW-JVBJWZIXSA-N 0.000 claims description 2
- ZKRGDRIWZDUEPQ-PMVMPFDFSA-N 5-[(1S,5S)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C)O[C@@H]1COCC1)C ZKRGDRIWZDUEPQ-PMVMPFDFSA-N 0.000 claims description 2
- IAMGOGVQPSKQQH-VXKWHMMOSA-N 5-[(1S,5S)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-propan-2-yloxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C)OC(C)C)C IAMGOGVQPSKQQH-VXKWHMMOSA-N 0.000 claims description 2
- IQSYFGKEPBJGRP-LJQANCHMSA-N 5-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C[C@@H](CC1)N(C)C)OC)C IQSYFGKEPBJGRP-LJQANCHMSA-N 0.000 claims description 2
- FJFKNVGKZVPRMF-HXUWFJFHSA-N 5-[(3R)-4,4-difluoro-1-methylpyrrolidin-3-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1CN(CC1(F)F)C)OC)C FJFKNVGKZVPRMF-HXUWFJFHSA-N 0.000 claims description 2
- UOQMXHXCLGTRJC-UYAOXDASSA-N 5-[(3R,4R)-3-(dimethylamino)-4-fluoropyrrolidin-1-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C[C@H]([C@@H](C1)F)N(C)C)OC)C UOQMXHXCLGTRJC-UYAOXDASSA-N 0.000 claims description 2
- JHNVZIXDACFDHW-WIYYLYMNSA-N 5-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1[C@@H](CN(CC1)C)F)OC)C JHNVZIXDACFDHW-WIYYLYMNSA-N 0.000 claims description 2
- UOQMXHXCLGTRJC-AZUAARDMSA-N 5-[(3R,4S)-3-(dimethylamino)-4-fluoropyrrolidin-1-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C[C@H]([C@H](C1)F)N(C)C)OC)C UOQMXHXCLGTRJC-AZUAARDMSA-N 0.000 claims description 2
- IQSYFGKEPBJGRP-IBGZPJMESA-N 5-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C[C@H](CC1)N(C)C)OC)C IQSYFGKEPBJGRP-IBGZPJMESA-N 0.000 claims description 2
- FJFKNVGKZVPRMF-FQEVSTJZSA-N 5-[(3S)-4,4-difluoro-1-methylpyrrolidin-3-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1CN(CC1(F)F)C)OC)C FJFKNVGKZVPRMF-FQEVSTJZSA-N 0.000 claims description 2
- QZZRPKOBISCONY-HSZRJFAPSA-N 5-[(4R)-1-cyclopropyl-3,3-difluoropiperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C1CC1)(F)F)OC)C QZZRPKOBISCONY-HSZRJFAPSA-N 0.000 claims description 2
- PTKRHBXNNDLRPO-LTGPVEHVSA-N 5-[(4R)-3,3-difluoro-1-(trideuteriomethyl)piperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trideuteriomethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C([2H])([2H])[2H])(F)F)OC([2H])([2H])[2H])C PTKRHBXNNDLRPO-LTGPVEHVSA-N 0.000 claims description 2
- GHGBEAPNWAOSDX-HSZRJFAPSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-6-methoxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinoline-3-carbonitrile Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=C(C=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC)C#N)C GHGBEAPNWAOSDX-HSZRJFAPSA-N 0.000 claims description 2
- PTKRHBXNNDLRPO-OAQYLSRUSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC)C PTKRHBXNNDLRPO-OAQYLSRUSA-N 0.000 claims description 2
- UWNQDRKSOGNBTH-XMMPIXPASA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-7-methoxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinoline-3-carbonitrile Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=C(C=NC2=CC(=CC(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC)C#N)C UWNQDRKSOGNBTH-XMMPIXPASA-N 0.000 claims description 2
- STUJRVJRAZLTQP-JOCHJYFZSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-7-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC(=CC(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC)C STUJRVJRAZLTQP-JOCHJYFZSA-N 0.000 claims description 2
- PTKRHBXNNDLRPO-CREDLSHTSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trideuteriomethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC([2H])([2H])[2H])C PTKRHBXNNDLRPO-CREDLSHTSA-N 0.000 claims description 2
- JYPFZIHUICGFBF-HXUWFJFHSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trifluoromethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC(F)(F)F)C JYPFZIHUICGFBF-HXUWFJFHSA-N 0.000 claims description 2
- SEKCYDQOHRZQLQ-GBXCKJPGSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)O[C@@H]1COCC1)C SEKCYDQOHRZQLQ-GBXCKJPGSA-N 0.000 claims description 2
- DQRXYWSHFHCKFK-HSZRJFAPSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-propan-2-yloxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC(C)C)C DQRXYWSHFHCKFK-HSZRJFAPSA-N 0.000 claims description 2
- MIRPQBODPPJQIV-HSZRJFAPSA-N 5-[(4R)-3,3-difluoro-1-propan-2-ylpiperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C(C)C)(F)F)OC)C MIRPQBODPPJQIV-HSZRJFAPSA-N 0.000 claims description 2
- KNMIRDATSJAIPW-HXUWFJFHSA-N 5-[(4R)-3,3-difluoropiperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CNCC1)(F)F)OC)C KNMIRDATSJAIPW-HXUWFJFHSA-N 0.000 claims description 2
- PTKRHBXNNDLRPO-NRFANRHFSA-N 5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC)C PTKRHBXNNDLRPO-NRFANRHFSA-N 0.000 claims description 2
- STUJRVJRAZLTQP-QFIPXVFZSA-N 5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-7-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC(=CC(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC)C STUJRVJRAZLTQP-QFIPXVFZSA-N 0.000 claims description 2
- PTKRHBXNNDLRPO-CZHKOJODSA-N 5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trideuteriomethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC([2H])([2H])[2H])C PTKRHBXNNDLRPO-CZHKOJODSA-N 0.000 claims description 2
- JYPFZIHUICGFBF-FQEVSTJZSA-N 5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-(trifluoromethoxy)quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC(F)(F)F)C JYPFZIHUICGFBF-FQEVSTJZSA-N 0.000 claims description 2
- SEKCYDQOHRZQLQ-RDPSFJRHSA-N 5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)O[C@@H]1COCC1)C SEKCYDQOHRZQLQ-RDPSFJRHSA-N 0.000 claims description 2
- DQRXYWSHFHCKFK-QHCPKHFHSA-N 5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-6-propan-2-yloxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC(C)C)C DQRXYWSHFHCKFK-QHCPKHFHSA-N 0.000 claims description 2
- JRYLIHMRXPLXCQ-GOSISDBHSA-N 5-[(7R)-7-fluoro-5-methyl-2,5-diazaspiro[3.4]octan-2-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(C[C@@H](C2)F)C)OC)C JRYLIHMRXPLXCQ-GOSISDBHSA-N 0.000 claims description 2
- JRYLIHMRXPLXCQ-SFHVURJKSA-N 5-[(7S)-7-fluoro-5-methyl-2,5-diazaspiro[3.4]octan-2-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(C[C@H](C2)F)C)OC)C JRYLIHMRXPLXCQ-SFHVURJKSA-N 0.000 claims description 2
- YHOXAOXMRAKRBS-LJQANCHMSA-N 5-[(8R)-8-fluoro-5-methyl-2,5-diazaspiro[3.5]nonan-2-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CC[C@H](C2)F)C)OC)C YHOXAOXMRAKRBS-LJQANCHMSA-N 0.000 claims description 2
- YHOXAOXMRAKRBS-IBGZPJMESA-N 5-[(8S)-8-fluoro-5-methyl-2,5-diazaspiro[3.5]nonan-2-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CC[C@@H](C2)F)C)OC)C YHOXAOXMRAKRBS-IBGZPJMESA-N 0.000 claims description 2
- FXPULUWIDCEJPG-UHFFFAOYSA-N 5-[2-(2,2-difluoroethyl)-2,6-diazabicyclo[3.2.0]heptan-6-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C2CCN(C2C1)CC(F)F)OC)C FXPULUWIDCEJPG-UHFFFAOYSA-N 0.000 claims description 2
- PTKRHBXNNDLRPO-BMSJAHLVSA-N 5-[3,3-difluoro-1-(trideuteriomethyl)piperidin-4-yl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)OC1C(CN(CC1)C([2H])([2H])[2H])(F)F)OC)C PTKRHBXNNDLRPO-BMSJAHLVSA-N 0.000 claims description 2
- HOXNBDRKOWZPGJ-UHFFFAOYSA-N 5-[3-(dimethylamino)azetidin-1-yl]-6-(2-fluoroethoxy)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(C1)N(C)C)OCCF)C HOXNBDRKOWZPGJ-UHFFFAOYSA-N 0.000 claims description 2
- JFFXGCPGUQZSLO-UHFFFAOYSA-N 5-[3-(dimethylamino)azetidin-1-yl]-6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(C1)N(C)C)NC=1OCC(N=1)(C)C)C JFFXGCPGUQZSLO-UHFFFAOYSA-N 0.000 claims description 2
- AHJJWEILIIBSLU-UHFFFAOYSA-N 5-[3-(dimethylamino)azetidin-1-yl]-6-ethoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(C1)N(C)C)OCC)C AHJJWEILIIBSLU-UHFFFAOYSA-N 0.000 claims description 2
- HPKDOXLDGGGXFV-UHFFFAOYSA-N 5-[3-(dimethylamino)azetidin-1-yl]-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC(C1)N(C)C)OC)C HPKDOXLDGGGXFV-UHFFFAOYSA-N 0.000 claims description 2
- OMAKMVHBVASUOW-UHFFFAOYSA-N 5-[3-(dimethylamino)cyclobutyl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)OC1CC(C1)N(C)C)OC)C OMAKMVHBVASUOW-UHFFFAOYSA-N 0.000 claims description 2
- OMUGBGGTLOVNDN-UHFFFAOYSA-N 5-[3-(dimethylamino)cyclopentyl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)OC1CC(CC1)N(C)C)OC)C OMUGBGGTLOVNDN-UHFFFAOYSA-N 0.000 claims description 2
- OTCROUTUWVSCAR-UHFFFAOYSA-N 5-[4-(dimethylamino)cyclohexyl]oxy-6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)OC1CCC(CC1)N(C)C)OC)C OTCROUTUWVSCAR-UHFFFAOYSA-N 0.000 claims description 2
- SETXXABQPISDAP-UHFFFAOYSA-N 6-(difluoromethoxy)-5-(7,7-difluoro-5-methyl-2,5-diazaspiro[3.4]octan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CC(C2)(F)F)C)OC(F)F)C SETXXABQPISDAP-UHFFFAOYSA-N 0.000 claims description 2
- SKUBYBNMCXOSOK-OALUTQOASA-N 6-(difluoromethoxy)-5-[(1S,5S)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C)OC(F)F)C SKUBYBNMCXOSOK-OALUTQOASA-N 0.000 claims description 2
- UAGDXSOSAVYDMC-HXUWFJFHSA-N 6-(difluoromethoxy)-5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC(F)F)C UAGDXSOSAVYDMC-HXUWFJFHSA-N 0.000 claims description 2
- JWYUXLONVOYXON-FGZHOGPDSA-N 6-cyclopropyloxy-5-[(1R,5R)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@@H]2CCN([C@@H]2C1)C)OC1CC1)C JWYUXLONVOYXON-FGZHOGPDSA-N 0.000 claims description 2
- JWYUXLONVOYXON-VXKWHMMOSA-N 6-cyclopropyloxy-5-[(1S,5S)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C)OC1CC1)C JWYUXLONVOYXON-VXKWHMMOSA-N 0.000 claims description 2
- XVTAQYVEQSIBAJ-HSZRJFAPSA-N 6-cyclopropyloxy-5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC1CC1)C XVTAQYVEQSIBAJ-HSZRJFAPSA-N 0.000 claims description 2
- XVTAQYVEQSIBAJ-QHCPKHFHSA-N 6-cyclopropyloxy-5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC1CC1)C XVTAQYVEQSIBAJ-QHCPKHFHSA-N 0.000 claims description 2
- ROATUQDMUFXUDZ-UHFFFAOYSA-N 6-methoxy-5-(1-methylpiperidin-4-yl)oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)OC1CCN(CC1)C)OC)C ROATUQDMUFXUDZ-UHFFFAOYSA-N 0.000 claims description 2
- KEIXAGCSTFTMCE-UHFFFAOYSA-N 6-methoxy-5-(1-methylpyrrolidin-3-yl)oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)OC1CN(CC1)C)OC)C KEIXAGCSTFTMCE-UHFFFAOYSA-N 0.000 claims description 2
- POOTUMJKGCKHDZ-UHFFFAOYSA-N 6-methoxy-5-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2CN(CC2C1)C)OC)C POOTUMJKGCKHDZ-UHFFFAOYSA-N 0.000 claims description 2
- AFRWAVVZFSRJTD-UHFFFAOYSA-N 6-methoxy-5-(3-methyl-3,6-diazabicyclo[3.2.0]heptan-6-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C2CN(CC2C1)C)OC)C AFRWAVVZFSRJTD-UHFFFAOYSA-N 0.000 claims description 2
- RIENFGUJMFHGDJ-UHFFFAOYSA-N 6-methoxy-5-(3-methyl-3,7-diazabicyclo[4.2.0]octan-7-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C2CCN(CC2C1)C)OC)C RIENFGUJMFHGDJ-UHFFFAOYSA-N 0.000 claims description 2
- MTXFCUIHSQTZQB-UHFFFAOYSA-N 6-methoxy-5-(4-methyl-2,3,4a,5,7,7a-hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2OCCN(C2C1)C)OC)C MTXFCUIHSQTZQB-UHFFFAOYSA-N 0.000 claims description 2
- DTLJNHFWGFMZSW-UHFFFAOYSA-N 6-methoxy-5-(4-methyl-3,3a,5,6,7,7a-hexahydro-2H-pyrrolo[3,2-b]pyridin-1-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CCC2N(CCCC21)C)OC)C DTLJNHFWGFMZSW-UHFFFAOYSA-N 0.000 claims description 2
- BPSSFAOHFNPNAN-UHFFFAOYSA-N 6-methoxy-5-(4-methylpiperazin-1-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CCN(CC1)C)OC)C BPSSFAOHFNPNAN-UHFFFAOYSA-N 0.000 claims description 2
- FPVKZTXDFNGSJV-UHFFFAOYSA-N 6-methoxy-5-(5-methyl-8-oxa-2,5-diazaspiro[3.5]nonan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)N(CCOC2)C)OC)C FPVKZTXDFNGSJV-UHFFFAOYSA-N 0.000 claims description 2
- BSKQBFZXCDWRIR-UHFFFAOYSA-N 6-methoxy-5-(6-methyl-2,6-diazabicyclo[3.2.0]heptan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1C2CN(C2CC1)C)OC)C BSKQBFZXCDWRIR-UHFFFAOYSA-N 0.000 claims description 2
- KJJCJDQFVDAFSG-UHFFFAOYSA-N 6-methoxy-5-(7-methyl-2,7-diazaspiro[3.4]octan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)CN(CC2)C)OC)C KJJCJDQFVDAFSG-UHFFFAOYSA-N 0.000 claims description 2
- MSZHNSKBDCRBTM-UHFFFAOYSA-N 6-methoxy-5-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)CCN(CC2)C)OC)C MSZHNSKBDCRBTM-UHFFFAOYSA-N 0.000 claims description 2
- BOLINYJVWIJFES-UHFFFAOYSA-N 6-methoxy-5-(8-methyl-5-oxa-2,8-diazaspiro[3.5]nonan-2-yl)-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CC2(C1)OCCN(C2)C)OC)C BOLINYJVWIJFES-UHFFFAOYSA-N 0.000 claims description 2
- JXQKQNNMNCWTIW-WOJBJXKFSA-N 6-methoxy-5-[(1R,5R)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@@H]2CCN([C@@H]2C1)C)OC)C JXQKQNNMNCWTIW-WOJBJXKFSA-N 0.000 claims description 2
- JXQKQNNMNCWTIW-PMACEKPBSA-N 6-methoxy-5-[(1S,5S)-2-methyl-2,6-diazabicyclo[3.2.0]heptan-6-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C)OC)C JXQKQNNMNCWTIW-PMACEKPBSA-N 0.000 claims description 2
- COBMGUYEAKMSGR-PMACEKPBSA-N 6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-5-[(1S,5S)-2-(2,2,2-trifluoroethyl)-2,6-diazabicyclo[3.2.0]heptan-6-yl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)CC(F)(F)F)OC)C COBMGUYEAKMSGR-PMACEKPBSA-N 0.000 claims description 2
- JXQKQNNMNCWTIW-YOCWRRKESA-N 6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-5-[(1S,5S)-2-(trideuteriomethyl)-2,6-diazabicyclo[3.2.0]heptan-6-yl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1[C@H]2CCN([C@H]2C1)C([2H])([2H])[2H])OC)C JXQKQNNMNCWTIW-YOCWRRKESA-N 0.000 claims description 2
- OEKIZKJCCSEQRO-UHFFFAOYSA-N 6-methoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-5-morpholin-4-ylquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)N1CCOCC1)OC)C OEKIZKJCCSEQRO-UHFFFAOYSA-N 0.000 claims description 2
- PTTYKDRAMIVLJB-UHFFFAOYSA-N 7-methoxy-5-(1-methylpiperidin-4-yl)oxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC(=CC(=C12)OC1CCN(CC1)C)OC)C PTTYKDRAMIVLJB-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- OCTIIGKPLDEYJH-HXUWFJFHSA-N N-[3-chloro-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-6-methoxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC)Cl OCTIIGKPLDEYJH-HXUWFJFHSA-N 0.000 claims description 2
- OCTIIGKPLDEYJH-FQEVSTJZSA-N N-[3-chloro-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]-5-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-6-methoxyquinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC=C(C(=C12)O[C@@H]1C(CN(CC1)C)(F)F)OC)Cl OCTIIGKPLDEYJH-FQEVSTJZSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- ALDFLMRHGPRKDW-ZTDHTWSHSA-N [5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl] 2,4-dimethylpiperazine-1-carboxylate Chemical compound CC1CN(CCN1C(=O)OC2=C(C3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OC5=CC6=NC=NN6C=N5)C)O[C@@H]7CCN(CC7(F)F)C)C ALDFLMRHGPRKDW-ZTDHTWSHSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 9
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- AREPNKQIYSOBDL-OAQYLSRUSA-N 5-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]oxy-6,7-dimethoxy-N-[3-methyl-4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)phenyl]quinazolin-4-amine Chemical compound N=1C=NN2C=NC(=CC2=1)OC1=C(C=C(C=C1)NC1=NC=NC2=CC(=C(C(=C12)O[C@H]1C(CN(CC1)C)(F)F)OC)OC)C AREPNKQIYSOBDL-OAQYLSRUSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024120830A JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2025150799A JP2026009898A (ja) | 2018-09-18 | 2025-09-11 | 抗腫瘍剤としてのキナゾリン誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/106098 | 2018-09-18 | ||
| CN2018106098 | 2018-09-18 | ||
| CNPCT/CN2019/091078 | 2019-06-13 | ||
| CN2019091078 | 2019-06-13 | ||
| PCT/CN2019/106233 WO2020057511A1 (en) | 2018-09-18 | 2019-09-17 | Quinazoline derivatives as antitumor agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120830A Division JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501338A JP2022501338A (ja) | 2022-01-06 |
| JPWO2020057511A5 true JPWO2020057511A5 (enExample) | 2022-09-28 |
| JP7546550B2 JP7546550B2 (ja) | 2024-09-06 |
Family
ID=69888359
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514381A Active JP7546550B2 (ja) | 2018-09-18 | 2019-09-17 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2024120830A Pending JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2025150799A Pending JP2026009898A (ja) | 2018-09-18 | 2025-09-11 | 抗腫瘍剤としてのキナゾリン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120830A Pending JP2024164018A (ja) | 2018-09-18 | 2024-07-26 | 抗腫瘍剤としてのキナゾリン誘導体 |
| JP2025150799A Pending JP2026009898A (ja) | 2018-09-18 | 2025-09-11 | 抗腫瘍剤としてのキナゾリン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11723908B2 (enExample) |
| EP (3) | EP3853220B1 (enExample) |
| JP (3) | JP7546550B2 (enExample) |
| KR (2) | KR20250171398A (enExample) |
| CN (2) | CN118255772A (enExample) |
| AU (2) | AU2019341273B2 (enExample) |
| CA (1) | CA3099776A1 (enExample) |
| DK (2) | DK3853220T3 (enExample) |
| ES (2) | ES2971927T3 (enExample) |
| FI (2) | FI4360713T3 (enExample) |
| HR (2) | HRP20240293T1 (enExample) |
| HU (2) | HUE069764T2 (enExample) |
| LT (2) | LT3853220T (enExample) |
| PL (2) | PL4360713T3 (enExample) |
| PT (2) | PT3853220T (enExample) |
| RS (2) | RS65413B1 (enExample) |
| SI (2) | SI3853220T1 (enExample) |
| SM (1) | SMT202400524T1 (enExample) |
| WO (1) | WO2020057511A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| LT3853220T (lt) * | 2018-09-18 | 2024-03-12 | F. Hoffmann-La Roche Ag | Chinazolino dariniai kaip antinavikiniai preparatai |
| CN111377850B (zh) * | 2018-12-31 | 2022-10-18 | 艾琪康医药科技（上海）有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| WO2021209039A1 (zh) * | 2020-04-17 | 2021-10-21 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| CN113527215B (zh) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| US20240246934A1 (en) * | 2021-03-19 | 2024-07-25 | Beijing Scitech-Mq Pharmaceuticals Limited | Quinazoline-based compound, composition, and application of quinazoline-based compound |
| US12037346B2 (en) | 2021-04-13 | 2024-07-16 | Nuvalent, Inc. | Amino-substituted heteroaryls for treating cancers with EGFR mutations |
| CN117858872A (zh) * | 2021-06-22 | 2024-04-09 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| US20240299387A1 (en) * | 2021-06-22 | 2024-09-12 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
| US20240300946A1 (en) * | 2021-06-22 | 2024-09-12 | Blueprint Medicines Corporation | Egfr inhibitors |
| CN117836286A (zh) * | 2021-06-22 | 2024-04-05 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| MX2024004738A (es) * | 2021-10-20 | 2024-05-14 | Hoffmann La Roche | Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas. |
| WO2023138675A1 (zh) * | 2022-01-21 | 2023-07-27 | 默达药物（香港）有限公司 | 喹啉化合物及其用途 |
| JP2025509830A (ja) * | 2022-03-14 | 2025-04-11 | フヤバイオ インターナショナル，エルエルシー | 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用 |
| KR20240167844A (ko) | 2022-03-28 | 2024-11-28 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
| TW202446386A (zh) * | 2023-04-14 | 2024-12-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 喹唑啉ＥｒｂＢ抑制劑的藥物形式 |
| WO2024249642A1 (en) * | 2023-06-02 | 2024-12-05 | Acerand Therapeutics (Hong Kong) Limited | Egfr inhibitors |
| TW202530231A (zh) * | 2023-09-27 | 2025-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹唑啉衍生物的可藥用鹽、其結晶形式及用途 |
| WO2025195333A1 (en) | 2024-03-19 | 2025-09-25 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation of erbb2 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012870A (es) | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
| CA2410562A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| HUP0401646A2 (hu) | 2001-11-03 | 2004-12-28 | Astrazeneca Ab, | Tumorellenes hatású kinazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2004000529A1 (de) | 2002-06-24 | 2003-12-31 | Fagerdala Deutschland Gmbh | Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| KR101028952B1 (ko) | 2003-08-14 | 2011-04-12 | 어레이 바이오파마 인크. | 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 |
| KR101086967B1 (ko) * | 2005-11-15 | 2011-11-29 | 어레이 바이오파마 인크. | 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물 |
| RU2009126576A (ru) | 2006-12-12 | 2011-01-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Конденсированное гетероциклическое соединение |
| JP6791979B2 (ja) | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| ES2873377T3 (es) | 2016-09-22 | 2021-11-03 | Inst Nat Sante Rech Med | Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón |
| US11578074B2 (en) | 2017-09-01 | 2023-02-14 | Shanghai Pharmaceuticals Holding Cd., Ltd. | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application |
| CN111630046B (zh) * | 2017-12-19 | 2023-01-10 | 成都金瑞基业生物科技有限公司 | 喹唑啉衍生物及其应用 |
| AR117424A1 (es) * | 2018-05-08 | 2021-08-04 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de los receptores erbb |
| CN112105618B (zh) | 2018-05-08 | 2022-05-31 | 南京明德新药研发有限公司 | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
| LT3853220T (lt) * | 2018-09-18 | 2024-03-12 | F. Hoffmann-La Roche Ag | Chinazolino dariniai kaip antinavikiniai preparatai |
-
2019
- 2019-09-17 LT LTEPPCT/CN2019/106233T patent/LT3853220T/lt unknown
- 2019-09-17 HR HRP20240293TT patent/HRP20240293T1/hr unknown
- 2019-09-17 WO PCT/CN2019/106233 patent/WO2020057511A1/en not_active Ceased
- 2019-09-17 SI SI201930718T patent/SI3853220T1/sl unknown
- 2019-09-17 CN CN202410230537.0A patent/CN118255772A/zh active Pending
- 2019-09-17 KR KR1020257038595A patent/KR20250171398A/ko active Pending
- 2019-09-17 DK DK19862146.8T patent/DK3853220T3/da active
- 2019-09-17 EP EP19862146.8A patent/EP3853220B1/en active Active
- 2019-09-17 HU HUE23219357A patent/HUE069764T2/hu unknown
- 2019-09-17 JP JP2021514381A patent/JP7546550B2/ja active Active
- 2019-09-17 PT PT198621468T patent/PT3853220T/pt unknown
- 2019-09-17 DK DK23219357.3T patent/DK4360713T3/da active
- 2019-09-17 ES ES19862146T patent/ES2971927T3/es active Active
- 2019-09-17 PT PT232193573T patent/PT4360713T/pt unknown
- 2019-09-17 US US17/051,176 patent/US11723908B2/en active Active
- 2019-09-17 CN CN201980044137.8A patent/CN112654612A/zh active Pending
- 2019-09-17 RS RS20240267A patent/RS65413B1/sr unknown
- 2019-09-17 FI FIEP23219357.3T patent/FI4360713T3/fi active
- 2019-09-17 PL PL23219357.3T patent/PL4360713T3/pl unknown
- 2019-09-17 AU AU2019341273A patent/AU2019341273B2/en active Active
- 2019-09-17 FI FIEP19862146.8T patent/FI3853220T3/fi active
- 2019-09-17 ES ES23219357T patent/ES3007082T3/es active Active
- 2019-09-17 PL PL19862146.8T patent/PL3853220T3/pl unknown
- 2019-09-17 EP EP24208940.7A patent/EP4523755A3/en active Pending
- 2019-09-17 EP EP23219357.3A patent/EP4360713B1/en active Active
- 2019-09-17 HU HUE19862146A patent/HUE065578T2/hu unknown
- 2019-09-17 SI SI201930872T patent/SI4360713T1/sl unknown
- 2019-09-17 LT LTEP23219357.3T patent/LT4360713T/lt unknown
- 2019-09-17 RS RS20241396A patent/RS66314B1/sr unknown
- 2019-09-17 KR KR1020217003251A patent/KR102889933B1/ko active Active
- 2019-09-17 SM SM20240524T patent/SMT202400524T1/it unknown
- 2019-09-17 CA CA3099776A patent/CA3099776A1/en active Pending
- 2019-09-17 HR HRP20241743TT patent/HRP20241743T1/hr unknown
-
2023
- 2023-05-18 US US18/319,509 patent/US20230293533A1/en active Pending
-
2024
- 2024-07-15 AU AU2024204847A patent/AU2024204847A1/en active Pending
- 2024-07-26 JP JP2024120830A patent/JP2024164018A/ja active Pending
-
2025
- 2025-09-11 JP JP2025150799A patent/JP2026009898A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020057511A5 (enExample) | ||
| HRP20240293T1 (hr) | Derivati kinazolina kao protutumorska sredstva | |
| US12486290B2 (en) | Isoindolinone and indazole compounds for the degradation of EGFR | |
| CN116323623B (zh) | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 | |
| JP2019517596A5 (enExample) | ||
| CN113490666A (zh) | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 | |
| IL282916B1 (en) | Fused cyclic chemical compounds and their uses in the treatment of ras-mediated diorders | |
| KR20250065935A (ko) | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| WO2025080592A1 (en) | Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer | |
| CN111527090B (zh) | 作为p2x3抑制剂的吡唑并-吡咯并-嘧啶-二酮衍生物 | |
| WO2017157792A1 (en) | Combinations of copanlisib | |
| US12145948B2 (en) | Compounds and methods for modulating HER2 | |
| US20200123147A1 (en) | Thiazole compounds useful as prmt5 inhibitors | |
| JP2024521791A (ja) | 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー | |
| CN114302878A (zh) | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 | |
| CN117440813A (zh) | 治疗脑或cns的癌转移的egfr降解剂 | |
| WO2019197269A1 (en) | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds | |
| US12404244B2 (en) | Pan-KIT kinase inhibitor having quinoline structure and application thereof | |
| JPWO2020052688A5 (enExample) | ||
| RU2789405C2 (ru) | Ингибитор киназы pan-kit, имеющий структуру хинолина, и его применение | |
| RU2023126005A (ru) | Производные пиразолопиридина и пути их применения | |
| NZ719050A (en) | Combination therapy combining a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| JP2023155223A (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤及びオーロラａ阻害剤を含む治療方法 |